Endothelin receptor antagonists and cerebral vasospasm

Clinical Autonomic Research

Volumn 14, Issue 3, 2004, Pages 143-145

  Zimmermann, Michael ^a   Seifert, Volker ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; BQ 610; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN RECEPTOR ANTAGONIST; TAK 044;

BRAIN VASOSPASM; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; EDITORIAL; HUMAN; MOLECULAR BIOLOGY; MORPHOMETRICS; NONHUMAN; PERFUSION;

EID: 3242679437     PISSN: 09599851     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10286-004-0186-y     Document Type: Editorial

References (14)

1. Chow M, Dumont AS, Kassell NF (2002) Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 51:1333-1341
2. Clozel M, Watanabe H (1993) BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 52: 825-834
3. Giller T, Breu V, Valdenaire O, et al. (1997) Absence of ET(B)-mediated contraction in Piebald-lethal mice. Life Sci 61:255-263
4. Juvela S (2000) Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 92:390-400
5. Matsumura Y, Ikegawa R, Suzuki Y, et al. (1991) Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci 49:841-848
6. Nayler WG (1990) Endothelin: isoforms, binding sites and possible implications in pathology. Trends Pharmacol Sci 11:96-99
7. Onoda K, Ono S, Ogihara K, et al. (1996) Inhibition of vascular contraction by intracisternal administration of preproendothelin-1 mRNA antisense oligoDNA in a rat experimental vasospasm model. J Neurosurg 85: 846-852
8. Seifert V, Loffler BM, Zimmermann M, et al. (1995) Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 82:55-62
9. Shaw MD, Vermeulen M, Murray GD, et al. (2000) Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 93:992-997
10. Yanagisawa M, Kurihara H, Kimura S, et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415
11. Zimmermann M, Jung C, Raabe A, et al. (2001) Inhibition of endothelin-converting enzyme activity in the rabbit basilar artery. Neurosurgery 48: 902-908
12. Zimmermann M, Seifert V (1998) Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 43: 863-875
13. Zimmermann M, Seifert V, Loffler BM, et al. (1996) Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 38:115-120
14. Zuccarello M, Soattin GB, Lewis AI, et al. (1996) Prevention of subarachnoid hemorrhage-induced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 84:503-507